机构名称：
¥ 11.0
Further raise innovation bar for diabetes treatment: – Approval of Ozempic ® 2.0 mg in the US – Successful completion of phase 3a trials with once-weekly insulin icodec – Successful completion of phase 2 trial with CagriSema in people with type 2 diabetes – Phase 1 trials with Ideal Pump insulin successfully completed – Phase 1 trial initiated with a once-daily oral GLP-1/GIP agonist and每周一次口服semaglutide
onecode
主要关键词
